Therapeutic strategies for Alzheimer's disease in clinical trials
Alzheimer's disease (AD) is considered to be the most common cause of dementia and is an
incurable, progressive neurodegenerative disorder. Current treatment of the disease …
incurable, progressive neurodegenerative disorder. Current treatment of the disease …
G-protein-coupled receptors in CNS: a potential therapeutic target for intervention in neurodegenerative disorders and associated cognitive deficits
Neurodegenerative diseases are a large group of neurological disorders with diverse
etiological and pathological phenomena. However, current therapeutics rely mostly on …
etiological and pathological phenomena. However, current therapeutics rely mostly on …
Therapeutic potential of multifunctional tacrine analogues
M Przybyłowska, S Kowalski… - Current …, 2019 - ingentaconnect.com
Tacrine is a potent inhibitor of cholinesterases (acetylcholinesterase and
butyrylcholinesterase) that shows limiting clinical application by liver toxicity. In spite of this …
butyrylcholinesterase) that shows limiting clinical application by liver toxicity. In spite of this …
A new serotonin 5-HT6 receptor antagonist with procognitive activity – Importance of a halogen bond interaction to stabilize the binding
JA González-Vera, RA Medina, M Martín-Fontecha… - Scientific reports, 2017 - nature.com
Serotonin 5-HT6 receptor has been proposed as a promising therapeutic target for cognition
enhancement though the development of new antagonists is still needed to validate these …
enhancement though the development of new antagonists is still needed to validate these …
AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer's Disease
AV Ivachtchenko, Y Lavrovsky… - Molecular …, 2016 - ACS Publications
Within the past decade several novel targets have been indicated as key players in
Alzheimer-type dementia and associated conditions, including a “frightening” memory loss …
Alzheimer-type dementia and associated conditions, including a “frightening” memory loss …
Neuropathic pain-alleviating effects of pyrazole-conjugated arylsulfonamides as 5-HT6 receptor antagonists
JR Hong, H Choo, G Nam - Bioorganic & Medicinal Chemistry Letters, 2017 - Elsevier
A novel series of arylsulfonylaminomethyl-3-(1-phenyl-5-isopropyl) pyrazoles was evaluated
for serotonin receptor subtype 6 (5-HT 6 R) antagonistic effects in vitro. We also investigated …
for serotonin receptor subtype 6 (5-HT 6 R) antagonistic effects in vitro. We also investigated …
5-HT6 receptor antagonist attenuates the memory deficits associated with neuropathic pain and improves the efficacy of gabapentinoids
P Jayarajan, R Nirogi, A Shinde, V Goura… - Pharmacological …, 2015 - Elsevier
Background Memory deficit is a co-morbid disorder in patients suffering from neuropathic
pain. Gabapentin and pregabalin (gabapentinoids) are among the widely prescribed …
pain. Gabapentin and pregabalin (gabapentinoids) are among the widely prescribed …
AVN-322 is a safe orally bio-available potent and highly selective antagonist of 5-HT6R with demonstrated ability to improve impaired memory in animal models
AV Ivachtchenko, YA Ivanenkov… - Current Alzheimer …, 2017 - ingentaconnect.com
Background: In recent years, 5-hydroxytryptamine subtype 6 receptor (5-HT6 receptor, 5-
HT6R) has emerged as a promising therapeutic target for the treatment of neuropathological …
HT6R) has emerged as a promising therapeutic target for the treatment of neuropathological …
[DOC][DOC] Preclinical evaluation of AVN-322, novel and highly selective 5-HT6 receptor antagonist, for the treatment of Alzheimer's disease
A Ivachtchenko, Y Ivanenkov, M Veselov - Curr Alzheimer Res, 2016 - avineuro.ru
In recent years, 5-hydroxytryptamine subtype 6 receptor (5-HT 6 receptor, 5-HT 6 R) has
rapidly emerged as a promising therapeutic target for the treatment of neuropathological …
rapidly emerged as a promising therapeutic target for the treatment of neuropathological …